MENLO PARK, Calif., Aug. 20 /PRNewswire/ -- ForteBio, Inc., a leading developer of label-free, real-time systems for biomolecular interaction analysis, announced today that it has signed two new distributors to sell and distribute its Octet System of instruments and related consumables. The company named Bucher Biotec AG, Switzerland, as its exclusive Swiss distributor and Millennium Science Pty Ltd, Australia, as its distribution partner in Australia and New Zealand. The announcement underscores the growing global demand for ForteBio’s life science analytical tools among pharmaceutical and biotechnology researchers.
“The expansion of our distribution network for the Octet System in both Europe and Australia will accelerate our efforts to further penetrate and serve these key markets,” said Winnie Wan, Ph.D., President and Chief Executive Officer. “We chose these two distributors because of their expertise and focus on drug-discovery technologies. Our objective is to meet the growing demand for label-free solutions that are flexible, cost-efficient and accurate.”
First launched in 2005, ForteBio’s Octet System is now offered in 32 countries, providing scientists with real-time information in therapeutic and bioprocessing development applications. The company’s analytical tools are designed to help accelerate the selection and characterization of therapeutic candidates by generating real-time kinetic and quantitative results quickly and easily.
Bucher Biotec AG (www.bucher.ch) is a privately held Swiss distributor that has represented major US, European and Japanese manufacturers of scientific instruments and associated consumables for life sciences research for nearly 30 years. Millennium Science Pty Ltd (www.mscience.com.au) is a specialist distribution company established in 1999 specifically to source, supply and support high technology solutions to the Australasian Life Science market. Millennium Science partners with carefully selected manufacturers who are, typically, market leaders in their chosen fields and are equally customer focused.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company providing analytical systems to accelerate the development of therapeutics. These systems enable real-time analysis of biomolecular interactions providing information on affinity, kinetics and concentration. Most importantly, ForteBio’s analytical capabilities enable better and faster characterization of drug candidates, thus providing greater value in drug development applications where existing methods have limitations in throughput, performance and cost. The company is headquartered in Menlo Park, California with a wholly owned subsidiary in Shanghai, China. For more information, please visit http://www.fortebio.com.
Contact: Winnie Wan, Ph.D. President and Chief Executive Officer 650-322-1360 wwan@fortebio.com
ForteBio, Inc.
CONTACT: Winnie Wan, Ph.D., President and Chief Executive Officer ofForteBio, Inc., +1-650-322-1360, wwan@fortebio.com
